Inactief instrument

Andere talen Hemispherx BioPharma, Inc Nyse

Aandelen

US42366C1036

slotkoers Nyse Andere beurzen
- ^USD	-

05/06	Transcript : AIM ImmunoTech Inc. - Special Call
16/05	Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Recent Stockholder Lawsuits In Delaware Challenge Common Advance Notice Bylaw Provisions	27/06
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference	10/06
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series	03/06
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering	31/05
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences	20/05
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update	16/05
AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast	09/05
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	06/05
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	29/04
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	29/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	25/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	18/04
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	15/04
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	11/04
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04
Challenges To Advance Notice Bylaws Are Spiking	08/04
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	02/04
North American Morning Briefing : Stocks Seen -2-	02/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hemispherx BioPharma, Inc Nyse

Aandelen

US42366C1036

Andere talen

Filters